Eli Lilly to continue other Covid-19 antibody drug trials after pausing one

Lilly said the government-sponsored clinical trial of its Covid-19 antibody treatment, which is similar to one taken by U.S. President Donald Trump, had been paused over safety concerns.

Eli Lilly & Co on Wednesday said that other trials of its experimental Covid-19 antibody drug will continue apace after it paused one ongoing trial of the drug, citing safety concerns.

The paused trial, which Lilly calls ACTIV-3, focused on hospitalized patients. Lilly said it differed from its other trials in some key respects, including the fact that the patients had more serious illness and were being treated with other drugs, including Gilead Sciences Inc’s remdesivir.

Lilly said in a statement that neutralizing antibody drugs such as bamlanivimab, which it is studying in Covid-19 patients, may be less beneficial for